# Immunovant (IMVT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IMVT
## Company Profile
- Ticker: IMVT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 30.26 USD
- Market cap: 6348151713.64 USD
- Last updated: 2026-10-08
## Business Overview
Immunovant is an immunology company focused on FcRn inhibition for autoantibody-driven diseases.
## Why The Stock Is Moving

As of Oct 8, 2026, IMVT closed down 5.56% at $30.26. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Immunovant sits in clinical-stage autoimmune biotechnology.

## Business Model

Its model is built around proof-of-concept data, dose optimization, and the potential to expand into multiple antibody-mediated diseases.

## Landscape Position

Immunovant is a catalyst-heavy immunology name whose stock reacts to clinical differentiation and platform confidence.

## Future Catalysts

- Immunovant is heading into a more important stretch around IMVT-1402. Management's latest framing highlights Recent Highlights and Upcoming Milestones: The Company announced preliminary Week 16 (end of Period 1) results from the IMVT-1402 trial in D2T RA with ACR20, ACR50, and ACR70.... The stock is likely to react most to whether those milestones keep moving without a reset.

## Recent News
- 2026-09-23 11:00 EST — [Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus](https://biopharmsignal.com/news/IMVT/immunovant-announces-topline-results-from-proof-of-concept-study-of-imvt-1402-in-a774c9f6) — Source: Immunovant
- 2026-08-06 11:00 EST — [Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026](https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-quar-73b76638) — Source: Immunovant
- 2026-07-23 20:05 EST — [Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026](https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-first-quarter-ended-june-30-2026--73653d45) — Source: Immunovant
- 2026-05-20 11:00 EST — [Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026](https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026) — Source: Immunovant
- 2026-05-11 20:05 EST — [Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026](https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provide-business-update-on-wednesday-may-20-2026) — Source: Immunovant